Epidemiology of Cancer in Kidney Transplant Recipients

IF 2.8 3区 医学 Q2 UROLOGY & NEPHROLOGY
David Massicotte-Azarniouch MD, MSc , J. Ariana Noel MD, MSc , Greg A. Knoll MD, MSc
{"title":"Epidemiology of Cancer in Kidney Transplant Recipients","authors":"David Massicotte-Azarniouch MD, MSc ,&nbsp;J. Ariana Noel MD, MSc ,&nbsp;Greg A. Knoll MD, MSc","doi":"10.1016/j.semnephrol.2024.151494","DOIUrl":null,"url":null,"abstract":"<div><p>Kidney transplantation is the ideal treatment modality for patients with end-stage kidney disease, with excellent outcomes post-transplant compared with dialysis. However, kidney transplant recipients are at increased risk of infections and cancer because of the need for immunosuppression. Kidney transplant recipients have approximately two to three times greater risk of developing cancer than the general population, and cancer is a major contributor to morbidity and mortality. Most of the increased risk is driven by viral-mediated cancers such as post-transplant lymphoproliferative disorder, anogenital cancers, and Kaposi sarcoma. Nonmelanoma skin cancer is the most frequent type of cancer in kidney transplant recipients, likely due to an interaction between ultraviolet radiation exposure and decreased immune surveillance. Occurrence of the more common types of solid organ cancers seen in the general population, such as breast, prostate, lung, and colorectal cancers, is not, or is only mildly, increased post-transplant. Clinical care and future research should focus on prevention and on improving outcomes for important immunosuppression-related malignancies, and treatment options for other cancers occurring in the transplant setting.</p></div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0270929524000111/pdfft?md5=99b92dccff332e7ea4e7c242ea388063&pid=1-s2.0-S0270929524000111-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nephrology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0270929524000111","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Kidney transplantation is the ideal treatment modality for patients with end-stage kidney disease, with excellent outcomes post-transplant compared with dialysis. However, kidney transplant recipients are at increased risk of infections and cancer because of the need for immunosuppression. Kidney transplant recipients have approximately two to three times greater risk of developing cancer than the general population, and cancer is a major contributor to morbidity and mortality. Most of the increased risk is driven by viral-mediated cancers such as post-transplant lymphoproliferative disorder, anogenital cancers, and Kaposi sarcoma. Nonmelanoma skin cancer is the most frequent type of cancer in kidney transplant recipients, likely due to an interaction between ultraviolet radiation exposure and decreased immune surveillance. Occurrence of the more common types of solid organ cancers seen in the general population, such as breast, prostate, lung, and colorectal cancers, is not, or is only mildly, increased post-transplant. Clinical care and future research should focus on prevention and on improving outcomes for important immunosuppression-related malignancies, and treatment options for other cancers occurring in the transplant setting.

肾移植受者的癌症流行病学。
肾移植是终末期肾病患者的理想治疗方式,与透析相比,肾移植后的疗效极佳。然而,由于需要免疫抑制,肾移植受者感染和罹患癌症的风险增加。肾移植受者罹患癌症的风险大约是普通人群的两到三倍,而癌症是导致发病率和死亡率的主要因素。风险增加的主要原因是病毒介导的癌症,如移植后淋巴增生性疾病、肛门癌和卡波西肉瘤。非黑色素瘤皮肤癌是肾移植受者中最常见的癌症类型,这可能是由于紫外线辐射和免疫监视功能下降之间的相互作用所致。一般人群中更常见的实体器官癌症,如乳腺癌、前列腺癌、肺癌和结肠直肠癌,在移植后的发病率并没有增加,或仅有轻微增加。临床护理和未来研究的重点应该是预防和改善重要的免疫抑制相关恶性肿瘤的治疗效果,以及移植环境中发生的其他癌症的治疗方案。Semin Nephrol 36:x-xx © 20XX Elsevier Inc.保留所有权利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Seminars in nephrology
Seminars in nephrology 医学-泌尿学与肾脏学
CiteScore
5.60
自引率
0.00%
发文量
27
审稿时长
6-12 weeks
期刊介绍: Seminars in Nephrology is a timely source for the publication of new concepts and research findings relevant to the clinical practice of nephrology. Each issue is an organized compendium of practical information that serves as a lasting reference for nephrologists, internists and physicians in training.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信